RJFSA
CASC

Raymond James Financial Services Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2,542
Closed -$25K – 2484
2016
Q3 		$25K Buy
+2,542
New +$18K ﹤0.01% 2240

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Raymond James Financial Services Advisors's CASC Position: Q4 2016 in Review

Raymond James Financial Services Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2016, closing a stake of 2,542 shares — an estimated $25K sold.

Raymond James Financial Services Advisors first reported a position in CASC in Q3 2016 and held it in 1 quarter. The position peaked at $25K in Q3 2016. 57 funds tracked by Wall St. Rank hold CASC as of Q4 2016.

  • Raymond James Financial Services Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 2,542 Cascadian Therapeutics, Inc. shares in Q4 2016, an estimated $25K.
  • Raymond James Financial Services Advisors first reported a position in Cascadian Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Cascadian Therapeutics, Inc. position peaked at $25K in Q3 2016.
  • 57 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2016.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2016, filed 9 Feb 2017.